Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 12/20 | 0.50 |
| ▸ | ESR2 | Q92731 | 6/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | PGR | P06401 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.42 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.42 |
| ▸ | ESRRA | P11474 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | PPARG | P37231 | 1/20 | 0.42 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.42 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6849122 | 0.91 | ESR1 (0.50) | ESR1ESR2HSD17B10AKR1C3TSHR | |
| SCHEMBL6849270 | 0.91 | ESR1 (0.50) | ESR1ESR2HSD17B10AKR1C3TSHR | |
| SCHEMBL6853734 | 0.91 | ESR1 (0.50) | ESR1ESR2HSD17B10AKR1C3TSHR | |
| SCHEMBL13807784 | 0.91 | ESR1 (0.50) | ESR1ESR2HSD17B10AKR1C3TSHR | |
| SCHEMBL4191325 | 0.91 | ESR1 (0.50) | ESR1ESR2HSD17B10AKR1C3TSHR | |
| SCHEMBL9972605 | 0.91 | ESR1 (0.50) | ESR1ESR2HSD17B10AKR1C3TSHR | |
| SCHEMBL6853827 | 0.90 | ESR1 (0.49) | ESR1ESR2HSD17B10AKR1C3TSHR | |
| SCHEMBL6849120 | 0.90 | ESR1 (0.49) | ESR1ESR2HSD17B10AKR1C3TSHR | |
| SCHEMBL7106646 | 0.90 | ESR1 (0.49) | ESR1ESR2HSD17B10AKR1C3TSHR | |
| SCHEMBL8381243 | 0.90 | ESR1 (0.49) | ESR1ESR2HSD17B10AKR1C3TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7538100-B2 | 17α-alkyl-17β-oxy-estratrienes and intermediate products for their production, use of the 17α-alkyl-17β-oxy-estratrienes for the production of pharmaceutical agents as well as pharmaceutical preparations | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-05-26 | — | — | US | disclosed |
| EP-1448591-B1 | 17ALPHA-ALKYL-17BETA-OXY-ESTRATRIENES AND INTERMEDIATES FOR THE PRODUCTION THEREOF, AND USE OF SAID 17ALPHA-ALKYL-17BETA-OXY-ESTRATRIENES FOR PRODUCING MEDICAMENTS AND PHARMACEUTICAL PREPARATIONS | BAYER SCHERING PHARMA AG (DE) | 2008-05-21 | — | — | EP | disclosed |
| EP-1916254-A2 | 17alpha-alkyl-17beta-oxy-estratriene and intermediates for its production, use of 17alpha-alkyl-17beta-oxy-estratriene for manufacturing medicine and pharmaceutical preparations | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-04-30 | — | — | EP | disclosed |
| US-7018994-B2 | 17α-ALKYL-17β-OXY-ESTRATRIENES AND INTERMEDIATE PRODUCTS FOR THEIR PRODUCTION, USE OF THE 17α-ALKYL-17β-OXY-ESTRATRIENES FOR THE PRODUCTION OF PHARMACEUTICAL AGENTS AS WELL AS PHARMACEUTICAL PREPARATIONS | SCHERING AG (DE) | 2006-03-28 | — | — | US | disclosed |
| US-20060009436-A1 | 17alpha-alkyl-17beta-oxy-estratrienes and intermediate products for their production, use of the 17alpha-alkyl-17beta-oxy-estratrienes for the production of pharmaceutical agents as well as pharmaceutical preparations | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2006-01-12 | — | — | US | disclosed |
| US-6780855-B2 | TREATING A PATIENT SUFFERING FROM AN ESTROGEN DEPENDENT-DISEASE | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-08-24 | — | — | US | disclosed |
| US-6677324-B1 | MIXTURE INCLUDES 7A-(E-AMINOALKYL)-ESTRATRIENE; HORMONE REPLACEMENT THERAPY; MENOPAUSE | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-01-13 | — | — | US | disclosed |
| US-20030191099-A1 | 17alpha-alkyl-17beta-oxy-estratrienes and intermediate products for their production, use of the 17alpha-alkyl-17beta-oxy-estratrienes for the production of pharmaceutical agents as well as pharmaceutical preparations | SCHERING AG (DE) | 2003-10-09 | — | — | US | disclosed |
| US-20030069434-A1 | 11BETA-HALOGEN-7ALPHA-SUBSTITUTED ESTRATRIENES, METOD FOR PRODUCING PHARMACEUTICAL PREPARATIONS CONTAINING SAID 11BETA-HALOGEN-7ALPHA- SUBSTITUTED ESTRATRIENES AND USE OF THE SAME FOR PRODUCING MEDICAMENTS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2003-04-10 | — | — | US | disclosed |
| EP-1042355-B1 | 11BETA-HALOGEN-7ALPHA-SUBSTITUTED ESTRATRIENES, METHOD FOR PRODUCING PHARMACEUTICAL PREPARATIONS CONTAINING SAID 11BETA-HALOGEN-7ALPHA-SUBSTITUTED ESTRATRIENES AND USE OF THE SAME FOR PRODUCING MEDICAMENTS | SCHERING AG (DE) | 2003-02-12 | — | — | EP | disclosed |
| EP-0920441-B1 | 7ALPHA-(EPSILON-AMINOALKYL)-ESTRATRIENES, PROCESS FOR PREPARING THE SAME, PHARMACEUTICAL PREPARATIONS CONTAINING SAID 7ALPHA-(EPSILON-AMINOALKYL)-ESTRATRIENES AND THEIR USE FOR PREPARING MEDICAMENT | SCHERING AG (DE) | 2003-01-29 | — | — | EP | disclosed |
| US-6271403-B1 | PURE ANTIESTROGENS, OR ESTROGENIC ANTIESTROGENS WITH ESTROGENIC PARTIAL ACTION. | SCHERING AKTIENGESELLSCHAFT (DE) | 2001-08-07 | — | — | US | disclosed |
| US-5986115-A | STEROIDS WITH FLUORO GROUPS AND ETHER OR ESTER GROUPS | SCHERING AG (DE) | 1999-11-16 | — | — | US | disclosed |
| US-5866560-A | ESTROGEN INHIBITORS; TUMOR THERAPY; HORMONE REPLACEMENT THERAPY | SCHERING AG (DE) | 1999-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060009436-A1 | 17alpha-alkyl-17beta-oxy-estratrienes and intermediate products for their production, use of the 17alpha-alkyl-17beta-oxy-estratrienes for the production of pharmaceutical agents as well as pharmaceutical preparations | CYP19A1, HSD17B11, CYP17A1 | ESR1 22/4885ESR2 27/4885HSD17B10 39/4885 |
| US-20030191099-A1 | 17alpha-alkyl-17beta-oxy-estratrienes and intermediate products for their production, use of the 17alpha-alkyl-17beta-oxy-estratrienes for the production of pharmaceutical agents as well as pharmaceutical preparations | CYP19A1, HSD17B11, CYP17A1 | ESR1 22/4885ESR2 31/4885HSD17B10 40/4885 |
| US-20030069434-A1 | 11BETA-HALOGEN-7ALPHA-SUBSTITUTED ESTRATRIENES, METOD FOR PRODUCING PHARMACEUTICAL PREPARATIONS CONTAINING SAID 11BETA-HALOGEN-7ALPHA- SUBSTITUTED ESTRATRIENES AND USE OF THE SAME FOR PRODUCING MEDICAMENTS | CYP19A1, HSD17B11, NR5A1 | ESR1 15/4885ESR2 14/4885HSD17B10 139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.